Background
==========

Clinical presentations from *Aspergillus fumigatus* infections range from mild (single organ involvement) to life-threatening invasive disease. Classically, these infections occur in immunosuppressed patients (neutropenic patients, bone marrow and solid organ transplant recipients, HIV/AIDS patients) or patients on immunosuppressive regimens such as corticosteroids and or, chemotherapy. There has been also increasing reports of IA in patients with non-classic risk factors (surgery, cirrhosis, chronic obstructive pulmonary disease, malignancy, and cystic fibrosis) as well as described in patients with systemic lupus erythematosus (SLE).

Occasionally, A. fumigatus infection displays unusual clinical features, posing a challenging diagnosis for the clinician. Failure to recognize and delays in treatment of these fungal infections increases the risk of an adverse clinical outcome. We present a case of invasive aspergillosis with unusual endobronchial features.

Case Report
===========

A 36-year-old-female with history of SLE was admitted to the ICU with hypoxemic respiratory failure. Her initial complaints included fever, shortness of breath, cough with sputum production, and ulcers in oral region for two weeks. The patient denied hemoptysis. Her SLE had affected the cutaneous and musculoskeletal systems. Although she was previously on metothrexate treatment, she had not been taking immunosuppresants for 6 months. She had a history of 20 pack/year tobacco use.

In the emergency department vital signs were significant for hypotension, tachycardia and tachypnea along with fever of 101.6°F (38.7°C) and spO2 93% on 4L/min via nasal cannula. Her physical exam was remarkable for respiratory distress, bibasilar lung dullness, and distal phalanx erythematous nodules ([Figure 1](#f1-amjcaserep-13-169){ref-type="fig"}). Her complete blood cell count showed a WBC 2.5×10^3^ cells/uL (neutrophilis 83%, lymphocytes 14%), hemoglobin 8.5 mg/dl, and platelet count 116 cells/uL. Her arterial blood gases were remarkable for hypoxemia. Chest radiograph displayed bilateral pulmonary infiltrates and pleural effusions ([Figure 2](#f2-amjcaserep-13-169){ref-type="fig"}).

Upon deterioration of her respiratory status and severe hypoxemia, she was admitted to the intensive care unit (ICU) and mechanical ventilation was initiated. On ICU day 1 a chest computed tomogram (CT) showed bibasilar infiltrates and bilateral pleural effusions ([Figure 3](#f3-amjcaserep-13-169){ref-type="fig"}). A flexible bronchoscopy (FB) with bronchoalveolar lavage (BAL) was performed. Right mainstem bronchus and right lower lobe endobronchial lesions were present ([Figure 4](#f4-amjcaserep-13-169){ref-type="fig"}). These white papular areas were amenable to sampling using a protected endobronchial brush. As her condition progressively deteriorated, antifungal coverage and stress dose steroids were initiated.

On ICU day 2, the BAL revealed growth of septated hyphae, consistent with *A. fumigatus*. Serum and BAL galactomannan assays were positive. Antifungal agent was changed to voriconazole. Her hospital stay was complicated with cardiogenic shock requiring Intra aortic balloon pump (IABP) and inotropics. Although an endomyocardial biopsy was not obtained secondary to her labile status, it was suspected that there was fungal involvement of her cardiovascular system. Prompt initiation of voriconazole resulted in progressive overall clinical improvement, and she was able to be weaned from the IABP, vasopressors, and mechanical ventilation. She remained hospitalized for a total of 30 days, to be discharged to skilled nursing facility. At one month out-patient follow-up the patient had returned to her baseline.

Discussion
==========

We describe an unusual presentation of aspergillus fumigatus infection, in which extensive endobronchial and possibly endomyocardial fungal involvement resulted in cardio-respiratory collapse. A variety of clinical manifestations have been described in *Aspergillus fumigatus* infection: 1) allergic bronchopulmonary aspergillosis (ABPA), 2) pulmonary aspergilloma, 3) chronic necrotizing pneumonia, and 4) invasive aspergillosis. In a series among intensive care unit patients, 3% of the autopsies displayed evidence of disseminated *A. fumigatus* infection. \[[@b1-amjcaserep-13-169],[@b2-amjcaserep-13-169]\] Patterns of endobronchial aspergillosis include: 1) mucous plugs in bronchiectatic areas; 2) endoluminal mass-like obstructive lesions; 3) bronchiolithiasis; 4) airway narrowing and abundant granulation tissue, especially in surgical anastomosis; 5) polypoid lesions; 6) eroded bronchial walls \[[@b2-amjcaserep-13-169]--[@b6-amjcaserep-13-169]\]. In cases of suspected aspergillus fumigatus pulmonary infection, a bronchoscopy with bronchioalveolar lavage is warranted, as this diagnostic modality is \>90% specific for detection of this organism \[[@b7-amjcaserep-13-169]\]. Our patient displayed signs of endobronchial involvement, although there was no visible obstruction, airway narrowing or mucosal erosion at the time of bronchoscopic examination.

Invasive aspergillosis complicating systemic lupus erythematosus is a rare entity, which carries a high mortality (\>95%) and may result in various sequelae \[[@b8-amjcaserep-13-169],[@b9-amjcaserep-13-169]\]. It has been described that SLE induced vasculitis may result in mucocutaneous breakdown, and impaired humoral and cellular immunity predispose these immunocompromised hosts to more severe forms of aspergillus fumigatus infection \[[@b10-amjcaserep-13-169],[@b11-amjcaserep-13-169]\].

Cutaneous manifestations of IA are a rare entity, and may be encountered in up to 2% of the patients with disseminated disease. Skin examination may display plaques or papules, often violaceous to erythematous. Later in the course of the disease, these lesions evolve into black eschars. The skin lesions present in our patient resolved within days of initiation of antifungal regimen \[[@b12-amjcaserep-13-169],[@b13-amjcaserep-13-169]\].

Although unconfirmed, it is possible that IA may have affected our patient's cardiovascular system. Aspergillus endomyocarditis carries a \>50% associated mortality, and should be included in the differential diagnosis in immunocompromised patients presenting with cardiocirculatory shock. In confirmed aspergillus endocarditis case, prompt surgical consultation should be sought, as an early aggressive surgical approach may be warranted \[[@b14-amjcaserep-13-169]\].

Pulmonary involvement in IA is usually multifocal and macronodular. Secondary invasion by A. fumigatus should be suspected in patients with evidence of new focal or nodular disease, especially on those with a history of previous fungal disease. Radiologically, nodules and cavitation may be encountered. The "halo" (mass with peripheral ground glass opacification) and "air crescent" (radiolucid crescents surrounding nodules) signs suggest pulmonary aspergillosis, although these finding may be absent among non-neutropenic patients \[[@b2-amjcaserep-13-169]\].

Especially in the fungal replication and growth phase, laboratory studies assist in the diagnosis of A. fumigatus infection. Galactomannan assay detects A. fumigatus wall components in body fluids. Brochioalveolar galactomannan positivity indicates respiratory involvement, whereas positive serum galactomannan assays raise the possibility of invasive fungal disease.

Treatment in invasive aspergillosis consists of intravenous antifungals (azoles, polyenes, echinocandins) and aggressive supportive measures. Early involvement of an infectious diseases specialist is suggested.

Conclusions
===========

This case highlights the importance of a high index of suspicion for fungal diseases, especially in critically ill hosts with endobronchial lesions. Our objective is to raise awareness of uncommon features of invasive aspergillosis, as adverse clinical outcomes may occur if these patterns are unrecognized by the clinician. The increasing incidence of IA in patients with active rheumatologic conditions, and its associated mortality among critically ill subjects warrants further research in this field.
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